title: Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
authors.forename: O
authors.initials: O
authors.lastname: Arslan
authors.forename: H
authors.initials: H
authors.lastname: Akan
authors.forename: H
authors.initials: H
authors.lastname: Koç
authors.forename: M
authors.initials: M
authors.lastname: Beksaç
authors.forename: O
authors.initials: O
authors.lastname: Ilhan
authors.forename: M
authors.initials: M
authors.lastname: Ozcan
authors.forename: S
authors.initials: S
authors.lastname: Yalçín
authors.forename: G
authors.initials: G
authors.lastname: Gürman
authors.forename: N
authors.initials: N
authors.lastname: Konuk
authors.forename: A
authors.initials: A
authors.lastname: Uysal
mesh_terms: D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000009:adverse effects*; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000009:adverse effects*; D004802:Eosinophilia / Q000453:epidemiology / Q000209:etiology*; D006086:Graft vs Host Disease / Q000097:blood* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D015994:Incidence; D007938:Leukemia / Q000150:complications / Q000628:therapy; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan; D008775:Methylprednisolone